FDA grants full approval to FILSPARI for FSGS, securing new royalty stream for Ligand
Ligand Pharmaceuticals (NASDAQ:LGND) announced on Tuesday, April 14, 2026, that its partner, Travere Therapeutics, has received full U.S. Food and Drug Administration (FDA) approval for FILSPARI (sparsentan).










